A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged ≥ 12 to < 18 years With Moderate-to- severe Atopic Dermatitis (AD) (ROCKET-Orbit)

  • Sharma, Niyati (Primary Chief Investigator (PCI))
  • Lai, Francis (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

HREC Reference Number: 2022/ETH02302
SSA Reference Number: SSA/98134/MonH-2023-373904(v1)
Monash Health Local Reference: RES-23-0000-318X
Effective start/end date22/06/2321/06/28